Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology's ...
ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...
The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...
The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...
Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...
A bladder cancer diagnosis can be overwhelming bringing uncertainty and emotional distress Read on to learn the hopes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback